Skip to main content
. 2017 Dec 8;17:815. doi: 10.1186/s12913-017-2758-2

Table 4.

Result of sensitivity analysis

Name of strategy Costs (US$) Effectiveness (DALYs) Incremental Costs Incremental Effectiveness (DALY averted) ICER (US$ / DALY averted) Annual CC incidence per 100,000 Remark
2 × screening per life time
 CS 8.05 0.00429 17.06
 NS alone 12.06 0.00414 4.01 0.00015 16.03 Dom
 CS + NV 18.32 0.00302 10.27 0.00127 8087 11.66 R
 NS + NV 21.84 0.00293 3.52 0.00009 39,111 11.03 NR
3 × screening per life time
 CS 8.07 0.00430 17.03
 NS alone 13.58 0.00413 5.51 0.00017 15.85 Dom
 CS + NV 18.26 0.00300 10.19 0.00130 7838 11.61 R
 NS + NV 23.31 0.00288 5.05 0.00012 42,083 10.80 NR
National screening programme achieving 40% coverage
 CS 8.02 0.00427 16.95
 NS alone 13.48 0.00402 5.46 0.00025 15.52 Dom
 CS + NV 18.16 0.00295 10.14 0.00132 7682 11.38 R
 NS + NV 23.00 0.00280 4.84 0.00015 32,267 10.49 NR
National screening programme achieving 60% coverage
 CS 7.98 0.00427 17.15
 NS alone 16.61 0.00387 8.63 0.00040 14.69 Dom
 CS + CV 18.26 0.00301 10.28 0.00126 8159 11.59 R
 NS + NV 25.98 0.00276 7.72 0.00025 30,880 10.10 NR
National vaccination programme achieving 90% coverage
 CS 8.02 0.00429 16.90
 NS alone 10.30 0.00420 2.28 0.00009 16.39 Dom
 CS + NV 21.70 0.00257 13.68 0.00172 7953 9.73 R
 NS + NV 23.53 0.00253 1.83 0.00004 45,750 9.46 NR
National vaccination programme achieving 50% coverage
 CS 8.00 0.00426 17.02
 NS alone 10.28 0.00417 2.28 0.00009 16.47 Dom
 CS + NV 15.65 0.00336 7.65 0.00090 8500 12.87 R
 NS + NV 17.67 0.00329 2.02 0.00007 28,857 12.48 NR

Cost-effectiveness threshold = US$ 9609.9/DALY averted

ICER=StrategycostCurrentscenariocostCurrentscenarioDALYslostStartegyDALYslost

Gavi vaccine price ($4.5/dose) used for all analysis

CS current scenario of opportunistic screening

NS, National cervical cancer screening, NV National HPV vaccination, DALY disability adjusted life years, CC cervical cancer, R recommended, NR not recommended, Dom dominated